Appointment of director & deputy chair

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces today the appointment of Martin Walton as a board director and deputy chair of the Group.

Martin Walton's appointment was approved in a resolution passed by the EDX Medical board of directors on Wednesday February 12.

Martin Walton has more than 35 years' experience in finance and investment, including 15 years working with global life sciences companies. He has completed multiple corporate transactions from spin-outs, seed- and growth- capital raises to MBOs, M&A, public market listings and sales to strategic and private equity buyers.

Jason Holt, chair of EDX Medical, commented: "We are very pleased to welcome someone of Martin's experience and expertise as deputy chair. He will be a great asset to the company. This year is extremely important in the development of the company as we continue to implement our business strategy through commercialisation and expansion of our product portfolio and the further development of sector partnerships. Martin will play a leading role in evaluating future strategic growth opportunities including consideration of progression to other public markets including the AIM market in London and a Hong Kong listing."

Professor Sir Chris Evans, OBE, founder of EDX Medical, said: "Martin and I have worked together closely for more than 22 years on multiple successful fund raisings and biotech transactions. Martin's long experience in various public markets will certainly benefit the company as we take forward our ambitious plans for the future."

Martin Walton said: "I am delighted to join the board of EDX Medical - a highly promising company - and to work again with Chris and the team. I will play an active role in helping drive forward our strategy to become an eminent developer and supplier of class-leading digital diagnostics. There is clear demand and need for earlier detection of disease and intervention on a global scale as well as providing the most advanced data driven solutions."

In accordance with Aquis Rule 4.9, Martin Walton has declared the following information. No other information is required to be disclosed.

Directorships:

The board of directors of EDX Medical plc accept responsibility for this announcement.